SOUTH SAN FRANCISCO, Calif.,
July 28, 2015 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it
will report its second quarter 2015 financial results after
market close on Tuesday, August 4,
2015. Rigel senior management will follow the announcement
with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial
results.
Participants can access the live conference call by dialing
855-892-1489 (domestic) or 720-634-2939 (international) and using
the Conference ID number 86332235. The conference call will
also be webcast live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and
available for replay for 30 days after the call via the Rigel
website.
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc. is a clinical-stage biotechnology
company focused on the discovery and development of novel,
small-molecule drugs for the treatment of inflammatory diseases,
autoimmune diseases, and cancers. Rigel's pioneering research
focuses on signaling pathways that are critical to disease
mechanisms. Rigel currently has the following product candidates in
development: fostamatinib, an oral spleen tyrosine kinase (SYK)
inhibitor, which is in Phase 3 clinical trials for ITP and a Phase
2 clinical trial for IgA nephropathy (IgAN); R348, a topical
ophthalmic JAK/SYK inhibitor, in a Phase 2 clinical trial for dry
eye in ocular graft-versus-host disease (GvHD); two oncology
product candidates in Phase 1 development with
partners BerGenBio AG and Daiichi Sankyo; and two
preclinical programs with partners AstraZeneca, for R256 in
asthma, and Bristol-Myers Squibb, for TGF beta inhibitors in
immuno-oncology.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
Media Contact:
Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
Logo -
http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2015-financial-results-300119391.html
SOURCE Rigel Pharmaceuticals, Inc.